Astellas gets FDA approval for Vyloy plus chemo to treat gut cancers
Vyloy is a cytolytic monoclonal antibody (mAb) therapy, together with chemotherapy, indicated for adults with locally advanced HER2-negative gastric or GEJ adenocarcinoma whose tumours are CLDN 18.2-positive
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry